BR112021022405A2 - Domínios variantes para multimerização de proteínas e separação das mesmas - Google Patents
Domínios variantes para multimerização de proteínas e separação das mesmasInfo
- Publication number
- BR112021022405A2 BR112021022405A2 BR112021022405A BR112021022405A BR112021022405A2 BR 112021022405 A2 BR112021022405 A2 BR 112021022405A2 BR 112021022405 A BR112021022405 A BR 112021022405A BR 112021022405 A BR112021022405 A BR 112021022405A BR 112021022405 A2 BR112021022405 A2 BR 112021022405A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- immunoglobulin
- separation
- multimerization
- variant
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 238000000926 separation method Methods 0.000 title abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 6
- 102000018358 immunoglobulin Human genes 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
domínios variantes para multimerização de proteínas e separação das mesmas. a presente invenção se refere a meios e métodos para produzir e isolar proteínas de imunoglobulina que compreendem um primeiro e um segundo polipeptídeo de imunoglobulina, em particular, a meios e métodos para produzir e separar proteínas que compreendem os ditos primeiro e segundo polipeptídeos de imunoglobulina. mediante a inclusão de variações de aminoácidos, e domínios de separação variantes de uma célula que produz a proteína de imunoglobulina desejada, uma proteína de imunoglobulina desejada conforme produzida pode ser separada de misturas de proteínas de imunoglobulina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19173633 | 2019-05-09 | ||
PCT/NL2020/050298 WO2020226502A2 (en) | 2019-05-09 | 2020-05-08 | Variant domains for multimerizing proteins and separation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021022405A2 true BR112021022405A2 (pt) | 2022-04-19 |
Family
ID=66476558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021022405A BR112021022405A2 (pt) | 2019-05-09 | 2020-05-08 | Domínios variantes para multimerização de proteínas e separação das mesmas |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210054049A1 (pt) |
EP (1) | EP3966238A2 (pt) |
JP (1) | JP2022534674A (pt) |
KR (1) | KR20220017909A (pt) |
CN (2) | CN114702587A (pt) |
AR (1) | AR118898A1 (pt) |
AU (1) | AU2020268684A1 (pt) |
BR (1) | BR112021022405A2 (pt) |
CA (1) | CA3139402A1 (pt) |
IL (1) | IL287928A (pt) |
MA (1) | MA55884A (pt) |
MX (1) | MX2021013646A (pt) |
SG (1) | SG11202112399PA (pt) |
TW (1) | TW202108613A (pt) |
WO (1) | WO2020226502A2 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019243665B2 (en) * | 2018-03-30 | 2023-06-01 | Merus N.V. | Multivalent antibody |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
US7135287B1 (en) * | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US6680209B1 (en) * | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
CA2872136C (en) | 2002-07-18 | 2017-06-20 | Merus B.V. | Recombinant production of mixtures of antibodies |
EP1737890A2 (en) * | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2007114325A1 (ja) * | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 二重特異性抗体を精製するための抗体改変方法 |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
MX369784B (es) * | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
AU2009263082C1 (en) | 2008-06-27 | 2018-11-01 | Merus N.V. | Antibody producing non-human mammals |
TWI461211B (zh) | 2009-03-20 | 2014-11-21 | Genentech Inc | 抗-her抗體 |
DK2766392T3 (da) * | 2011-10-10 | 2019-10-07 | Xencor Inc | Fremgangsmåde til oprensning af antistoffer |
ES2743399T3 (es) * | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
AU2014232501C1 (en) * | 2013-03-15 | 2021-04-22 | Xencor, Inc. | Heterodimeric proteins |
WO2015130172A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibodies that bind egfr and erbb3 |
EP3174897B1 (en) * | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
MA41375A (fr) * | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
MX2018015331A (es) * | 2016-06-10 | 2019-08-16 | Eisai R&D Man Co Ltd | Inmunglobulinas conjugadas con lisina. |
CA3068929A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
KR20200037250A (ko) | 2017-07-06 | 2020-04-08 | 메뤼스 엔.페. | 세포에 의해 발현되는 생물학적 활성을 조절하는 항체 |
EP3649155A1 (en) | 2017-07-06 | 2020-05-13 | Merus N.V. | Bispecific anti pd1-anti tim3 antibodies |
SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
AU2019243665B2 (en) | 2018-03-30 | 2023-06-01 | Merus N.V. | Multivalent antibody |
-
2020
- 2020-05-08 CN CN202210393772.0A patent/CN114702587A/zh active Pending
- 2020-05-08 CA CA3139402A patent/CA3139402A1/en active Pending
- 2020-05-08 EP EP20727737.7A patent/EP3966238A2/en active Pending
- 2020-05-08 MA MA055884A patent/MA55884A/fr unknown
- 2020-05-08 SG SG11202112399PA patent/SG11202112399PA/en unknown
- 2020-05-08 WO PCT/NL2020/050298 patent/WO2020226502A2/en unknown
- 2020-05-08 JP JP2021566278A patent/JP2022534674A/ja active Pending
- 2020-05-08 TW TW109115418A patent/TW202108613A/zh unknown
- 2020-05-08 KR KR1020217039330A patent/KR20220017909A/ko unknown
- 2020-05-08 AU AU2020268684A patent/AU2020268684A1/en active Pending
- 2020-05-08 CN CN202080048983.XA patent/CN114430745A/zh active Pending
- 2020-05-08 MX MX2021013646A patent/MX2021013646A/es unknown
- 2020-05-08 AR ARP200101330A patent/AR118898A1/es unknown
- 2020-05-08 US US16/870,715 patent/US20210054049A1/en active Pending
- 2020-05-08 BR BR112021022405A patent/BR112021022405A2/pt unknown
-
2021
- 2021-11-08 IL IL287928A patent/IL287928A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA55884A (fr) | 2022-03-16 |
WO2020226502A2 (en) | 2020-11-12 |
CN114430745A (zh) | 2022-05-03 |
WO2020226502A9 (en) | 2022-03-03 |
WO2020226502A3 (en) | 2021-02-04 |
CN114702587A (zh) | 2022-07-05 |
JP2022534674A (ja) | 2022-08-03 |
IL287928A (en) | 2022-01-01 |
US20210054049A1 (en) | 2021-02-25 |
CA3139402A1 (en) | 2020-11-12 |
EP3966238A2 (en) | 2022-03-16 |
KR20220017909A (ko) | 2022-02-14 |
AR118898A1 (es) | 2021-11-10 |
SG11202112399PA (en) | 2021-12-30 |
AU2020268684A1 (en) | 2021-12-09 |
MX2021013646A (es) | 2022-01-31 |
TW202108613A (zh) | 2021-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
BR112016013138A2 (pt) | mistura de peptídeos | |
PE20121539A1 (es) | Polipeptidos de la hormona de crecimiento y metodos de preparacion | |
BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
BR112017001340A2 (pt) | vacinas antidengue e anticorpos | |
BR112018071686A2 (pt) | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus | |
PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
BR112019002505A2 (pt) | método para produzir um agregado de proteína recombinante, e, agregado de proteína recombinante. | |
BR112017014580A8 (pt) | Método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína | |
BR112018071283A2 (pt) | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. | |
BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
BR112018071107A2 (pt) | composições e métodos para a detecção de proteínas da célula hospedeira | |
BR112017001463A2 (pt) | célula hospedeira melhorada para produzir proteínas | |
MX2020000288A (es) | Cromatografia. | |
MX2017015927A (es) | Fragmentos mutantes de proteina ras. | |
CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
BR112017028550A2 (pt) | proteínas de fusão de fragmentos de proteína humana para criar composições de inmunoglobulina fc multimerizadas ordinárias com relação de complemento melhorado | |
BR112021022405A2 (pt) | Domínios variantes para multimerização de proteínas e separação das mesmas | |
MX2017009253A (es) | Anticuerpos antiglicoproteina y usos de los mismos. | |
EA202191699A1 (ru) | Способы для охарактеризования дисульфидных связей | |
WO2021239838A3 (en) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |